A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy (disease response) and safety of
mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects
with advanced non-small cell lung cancer (NSCLC).